Comparison of Intermittent Fasting and Caloric Deficit for Weight Loss in Women With Polycystic Ovarian Syndrome

Intermittent Fasting and Polycystic Ovarian Syndrome

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04452968

Enrollment

Registered

2020-07-01

Start date

2020-07-01

Completion date

2020-10-30

Last updated

2020-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intermittent Fasting, Polycystic Ovarian Syndrome, Weight Loss

Brief summary

Time restricted feeding (TRF) has been emerging as a potential weight loss strategy that avoids major dietary changes but achieves strong effects. It also improves insulin sensitivity through increased human growth hormone. This effect helps to improve the root cause of weight gain and has additional benefits for women with PCOS.

Interventions

BEHAVIORALintermittent fasting

Women were required to fast for 16 hours and consume their allotted calories during the remaining 8 hours.

BEHAVIORALCaloric restriction

Daily caloric requirement was calculated using basal metabolic rate (BMR) calculator. All women were directed to decrease calorie intake by 500 calories.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 35 Years

Healthy volunteers

Inclusion criteria

* PCOS as described by Rotterdam's criteria

Exclusion criteria

* endocrine disorders * diabetic * hypertensive * Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician; * The body weight fluctuated more than 5% in recent 3 months. * Liver and kidney dysfunction: renal impairment, creatinine clearance rate \< 30 mL/min/1.73 m2, transaminase increased, more than three times higher than the normal limit; * History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months; * History of thyroid diseases; * pregnant * Currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) * Patients who cannot be followed for 16 months (due to a health situation or migration) * Patients who are unwilling or unable to give informed consent

Design outcomes

Primary

Measure	Time frame
weight loss in kg	in 3 months

Secondary

Measure	Time frame
decrease in body fat percentage	in 3 months
fasting plasma insulin	in 3 months
blood pressure in mm Hg	in 3 months

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026